OR WAIT null SECS
December 14, 2016
BMS changes its US geographic footprint with R&D investments and closures.
December 08, 2016
At the American Society of Hematology Annual Meeting, Novartis and Kite Pharma both released results from early-phase clinical trials with CAR-T therapies.
Spark Therapeutics and Selecta entered a license agreement for Selecta’s gene-therapy co-administration technology.
December 07, 2016
Takeda and Lightstone have launched Cerevance, a neuroscience company focused on developing therapeutics for neurological and psychiatric disorders.
JHL Biotech and Sanofi collaborate on the development and commercialization of biological therapeutics in China.
December 02, 2016
Boehringer Ingelheim and China Southeast University announced a joint research collaboration to develop new regenerative treatments for hearing loss.
AstraZeneca entered a collaboration with Bicycle Therapeutics for the identification and development of bicyclic peptides.
November 30, 2016
Takeda will invest more than 100 million Euros to build a new manufacturing plant for its dengue vaccine candidate in Singen, Germany.
November 29, 2016
Mylan signed a sub-license agreement with the Medicines Patent Pool to develop a generic version of daclatasvir to market in developing countries.
November 23, 2016
The acquisition boosts Allergan’s CNS R&D pipeline and adds development programs focused on treatment for Alzheimer’s disease.